FDA Approves Emicizumab-kxwh for Hemophilia A With or Without Factor VIII Inhibitors

Oct 05

2018

The Food and Drug Administration approved emicizumab-kxwh injection (HEMLIBRA, Genentech, Inc.) for prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients (ages newborn and older) with hemophilia A (congenital factor VIII deficiency) with or without factor VIII (FVIII) inhibitors.

Citations

APA

American Society of Hematology. (2018).
FDA Approves Emicizumab-kxwh for Hemophilia A With or Without Factor VIII Inhibitors.
Retrieved from https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2018/fda-approves-emicizumab-kxwh-hemophilia-a-with-without-factor-viii-inhibitors.

Chicago

American Society of Hematology.
"FDA Approves Emicizumab-kxwh for Hemophilia A With or Without Factor VIII Inhibitors." Hematology.org.
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2018/fda-approves-emicizumab-kxwh-hemophilia-a-with-without-factor-viii-inhibitors
(label-accessed December 13, 2024).

MLA

"American Society of Hematology."
FDA Approves Emicizumab-kxwh for Hemophilia A With or Without Factor VIII Inhibitors, 13 Dec. 2024 ,
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2018/fda-approves-emicizumab-kxwh-hemophilia-a-with-without-factor-viii-inhibitors.

Citation Manager Formats

BibLaTeX
Bookends
EasyBib
EndNote
Mendeley
Papers
RIS
Ref Manager
RefWorks
Zotero

Help ASH Build an Inclusive Hematology Community!

ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.

How Can You Help?

Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!

Update Access to Demographic Information Learn About Our Mission